Literature DB >> 10738249

Localisation by in situ hybridisation of S100A4 (p9Ka) mRNA in primary human breast tumour specimens.

L L Nikitenko1, B H Lloyd, P S Rudland, S Fear, R Barraclough.   

Abstract

Rodent S100A4 (p9Ka) induces a metastatic phenotype in benign rat mammary tumour cells and cooperates with the neu oncogene to produce metastatic tumours in a transgenic mouse model system. Human S100A4 possesses similar metastasis-inducing properties. S100A4 mRNA is now sought in human breast tumour-derived cell lines and tumour specimens. S100A4 mRNA is present in some cell lines derived from malignant breast cancers, but is not detectable in cells derived from benign breast tumours. In human tumour specimens, using in situ hybridisation, the mRNA for S100A4 is localised to the epithelial cells of carcinoma specimens, and in some normal breast specimens, to a stromal region surrounding the epithelial ducts. In carcinoma specimens, S100A4 mRNA is also found in the stromal region surrounding islands of cancer cells. For both the epithelial and stromal components, S100A4 mRNA is present at a higher level in carcinomas relative to benign breast tumour specimens. In general, there is a concordance between the S100A4 mRNA signal from the epithelial and stromal elements of the same carcinoma specimens. Using Northern blotting techniques, these results have been extended to a panel of 137 benign and malignant breast tumour specimens. The results show that S100A4 mRNA occurs in the more-malignant, rather than in the more-benign tumour specimens. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10738249     DOI: 10.1002/(sici)1097-0215(20000415)86:2<219::aid-ijc11>3.0.co;2-7

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

Review 1.  Epithelial-mesenchymal transitions and the intersecting cell fate of fibroblasts and metastatic cancer cells.

Authors:  Eric G Neilson; David Plieth; Christo Venkov
Journal:  Trans Am Clin Climatol Assoc       Date:  2003

2.  1H, 13C, 15N NMR sequence-specific resonance assignments for human apo-Mts1 (S100A4).

Authors:  R Rustandi; K M Vallely; O Varlamova; M G Klein; S C Almo; A R Bresnick; D J Weber
Journal:  J Biomol NMR       Date:  2001-04       Impact factor: 2.835

3.  S100A7 has an oncogenic role in oral squamous cell carcinoma by activating p38/MAPK and RAB2A signaling pathway.

Authors:  K K Dey; R Bharti; G Dey; I Pal; Y Rajesh; S Chavan; S Das; C K Das; B C Jena; P Halder; J G Ray; I Kulavi; M Mandal
Journal:  Cancer Gene Ther       Date:  2016-10-21       Impact factor: 5.987

Review 4.  S100 proteins in cancer.

Authors:  Anne R Bresnick; David J Weber; Danna B Zimmer
Journal:  Nat Rev Cancer       Date:  2015-02       Impact factor: 60.716

5.  Psoriasin (S100A7) expression is altered during skin tumorigenesis.

Authors:  Salem Alowami; Gefei Qing; Ethan Emberley; Linda Snell; Peter H Watson
Journal:  BMC Dermatol       Date:  2003-02-24

6.  Expression of S100A4, E-cadherin, alpha- and beta-catenin in breast cancer biopsies.

Authors:  K B Pedersen; J M Nesland; Ø Fodstad; G M Maelandsmo
Journal:  Br J Cancer       Date:  2002-11-18       Impact factor: 7.640

7.  S100A4 (p9Ka) protein in colon carcinoma and liver metastases: association with carcinoma cells and T-lymphocytes.

Authors:  S Taylor; S Herrington; W Prime; P S Rudland; R Barraclough
Journal:  Br J Cancer       Date:  2002-02-01       Impact factor: 7.640

8.  Distinct prognostic values of S100 mRNA expression in breast cancer.

Authors:  Shizhen Zhang; Zhen Wang; Weiwei Liu; Rui Lei; Jinlan Shan; Ling Li; Xiaochen Wang
Journal:  Sci Rep       Date:  2017-01-04       Impact factor: 4.379

9.  Mechanistic attributes of S100A7 (psoriasin) in resistance of anoikis resulting tumor progression in squamous cell carcinoma of the oral cavity.

Authors:  Kaushik Kumar Dey; Siddik Sarkar; Ipsita Pal; Subhasis Das; Goutam Dey; Rashmi Bharti; Payel Banik; Joygopal Roy; Sukumar Maity; Indranil Kulavi; Mahitosh Mandal
Journal:  Cancer Cell Int       Date:  2015-07-29       Impact factor: 5.722

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.